Advertisement

Prognostic factors for actual long-term survival in the era of multidisciplinary treatment for pancreatic ductal adenocarcinoma

  • Kenji Nakagawa
  • Takahiro Akahori
  • Satoshi Nishiwada
  • Minako Nagai
  • Kota Nakamura
  • Toshihiro Tanaka
  • Tetsuro Tamamoto
  • Chiho Ohbayashi
  • Masatoshi Hasegawa
  • Kimihiko Kichikawa
  • Naoya Ikeda
  • Masayuki Sho
ORIGINAL ARTICLE

Abstract

Purpose

Recent advances in multidisciplinary treatments are improving the postoperative prognosis of pancreatic ductal adenocarcinoma (PDAC). However, the prognosis even after potentially curative resection remains poor. The aim of this study was to identify the clinical and pathological features of actual 5-year survivors under current circumstances.

Methods

A total of 128 patients who underwent pancreatectomy for PDAC at our institution between January 2006 and December 2011 were retrospectively analyzed.

Results

The actual 5-year overall survival rate for all patients was 30.9%, with a median survival time of 33.1 months. Of 128 patients, 25 (19.5%) survived for 5 years after surgery without disease recurrence. A univariate analysis showed that the pretreatment serum CA19–9 value, tumor depth, lymph node metastasis, and UICC stage at resection were significant predictive factors for the actual long-term survival. A multivariate analysis showed that a pretreatment serum CA19–9 value ≥ 110 U/mL was a significant unfavorable prognostic indicator. In addition, all subjects in the 5-year survival group completed adjuvant chemotherapy. The recurrence rate in the liver was significantly lower and that in the lung significantly higher in the long-term survival group than in the short-term survival group.

Conclusions

The factors contributing to the long-term survival of PDAC were the pretreatment CA19–9 value and the completion of adjuvant chemotherapy. To achieve the actual long-term survival and cure after pancreatectomy for pancreatic cancer, further treatment strategies enhancing the completion rate of adjuvant chemotherapy are required.

Keywords

Pancreatic cancer Multidisciplinary treatment Actual long-term survival Prognostic factor 

Notes

Authors’ contributions

Study conception and design: Kenji Nakagawa and Masayuki Sho; acquisition of data: all authors; analysis and interpretation of data: all authors; drafting the manuscript: Kenji Nakagawa and Masayuki Sho; critical revision of the manuscript: all authors.

Compliance with ethical standards

Conflict of interest

The authors declare that they have no conflict of interest.

Ethical approval

All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. This retrospective study was conducted with the approval of the Nara Medical University Hospital Institutional Review Board (No.1557).

Informed consent

Informed consent was obtained from all individual participants included in the study.

References

  1. 1.
    Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D (2011) Global cancer statistics. CA Cancer J Clin 61(2):69–90.  https://doi.org/10.3322/caac.20107 CrossRefPubMedGoogle Scholar
  2. 2.
    Hirata K, Sato T, Mukaiya M, Yamashiro K, Kimura M, Sasaki K, Denno R (1997) Results of 1001 pancreatic resections for invasive ductal adenocarcinoma of the pancreas. Arch Surg 132(7):771–776 discussion 777CrossRefGoogle Scholar
  3. 3.
    Wagner M, Redaelli C, Lietz M, Seiler CA, Friess H, Buchler MW (2004) Curative resection is the single most important factor determining outcome in patients with pancreatic adenocarcinoma. Br J Sur 91(5):586–594.  https://doi.org/10.1002/bjs.4484 CrossRefGoogle Scholar
  4. 4.
    Kimura K, Amano R, Nakata B, Yamazoe S, Hirata K, Murata A, Miura K, Nishio K, Hirakawa T, Ohira M, Hirakawa K (2014) Clinical and pathological features of five-year survivors after pancreatectomy for pancreatic adenocarcinoma. World J Surg Oncol 12:360.  https://doi.org/10.1186/1477-7819-12-360 CrossRefPubMedPubMedCentralGoogle Scholar
  5. 5.
    Schnelldorfer T, Ware AL, Sarr MG, Smyrk TC, Zhang L, Qin R, Gullerud RE, Donohue JH, Nagorney DM, Farnell MB (2008) Long-term survival after pancreatoduodenectomy for pancreatic adenocarcinoma: is cure possible? Ann Surg 247(3):456–462.  https://doi.org/10.1097/SLA.0b013e3181613142 CrossRefGoogle Scholar
  6. 6.
    Perysinakis I, Avlonitis S, Georgiadou D, Tsipras H, Margaris I (2015) Five-year actual survival after pancreatoduodenectomy for pancreatic head cancer. ANZ J Sur 85(3):183–186.  https://doi.org/10.1111/ans.12422 CrossRefGoogle Scholar
  7. 7.
    Picozzi VJ, Oh SY, Edwards A, Mandelson MT, Dorer R, Rocha FG, Alseidi A, Biehl T, Traverso LW, Helton WS, Kozarek RA (2017) Five-year actual overall survival in resected pancreatic cancer: a contemporary single-institution experience from a multidisciplinary perspective. Ann Surg Oncol 24(6):1722–1730.  https://doi.org/10.1245/s10434-016-5716-z CrossRefPubMedGoogle Scholar
  8. 8.
    Shimada K, Sakamoto Y, Nara S, Esaki M, Kosuge T, Hiraoka N (2010) Analysis of 5-year survivors after a macroscopic curative pancreatectomy for invasive ductal adenocarcinoma. World J Surg 34(8):1908–1915.  https://doi.org/10.1007/s00268-010-0570-9 CrossRefPubMedGoogle Scholar
  9. 9.
    Han SH, Heo JS, Choi SH, Choi DW, Han IW, Han S, You YH (2017) Actual long-term outcome of T1 and T2 pancreatic ductal adenocarcinoma after surgical resection. Int J Surg 40:68–72.  https://doi.org/10.1016/j.ijsu.2017.02.007 CrossRefPubMedGoogle Scholar
  10. 10.
    Ferrone CR, Brennan MF, Gonen M, Coit DG, Fong Y, Chung S, Tang L, Klimstra D, Allen PJ (2008) Pancreatic adenocarcinoma: the actual 5-year survivors. J Gastrointestinal Surg 12(4):701–706.  https://doi.org/10.1007/s11605-007-0384-8 CrossRefGoogle Scholar
  11. 11.
    Katz MH, Wang H, Fleming JB, Sun CC, Hwang RF, Wolff RA, Varadhachary G, Abbruzzese JL, Crane CH, Krishnan S, Vauthey JN, Abdalla EK, Lee JE, Pisters PW, Evans DB (2009) Long-term survival after multidisciplinary management of resected pancreatic adenocarcinoma. Ann Surg Oncol 16(4):836–847.  https://doi.org/10.1245/s10434-008-0295-2 CrossRefPubMedPubMedCentralGoogle Scholar
  12. 12.
    Clavien PA, Barkun J, de Oliveira ML, Vauthey JN, Dindo D, Schulick RD, de Santibanes E, Pekolj J, Slankamenac K, Bassi C, Graf R, Vonlanthen R, Padbury R, Cameron JL, Makuuchi M (2009) The Clavien-Dindo classification of surgical complications: five-year experience. Ann Surg 250(2):187–196.  https://doi.org/10.1097/SLA.0b013e3181b13ca2 CrossRefPubMedGoogle Scholar
  13. 13.
    Dindo D, Demartines N, Clavien PA (2004) Classification of surgical complications: a new proposal with evaluation in a cohort of 6336 patients and results of a survey. Ann Surg 240(2):205–213CrossRefGoogle Scholar
  14. 14.
    Sho M, Tanaka T, Yamada T, Nomi T, Akahori T, Doh J, Yamato I, Hokuto D, Nishiofuku H, Marugami N, Kanehiro H, Kichikawa K, Nakajima Y (2011) Novel postoperative adjuvant strategy prevents early hepatic recurrence after resection of pancreatic cancer. J Hepatobiliary Pancreat Sci 18(2):235–239; discussion 239-240.  https://doi.org/10.1007/s00534-010-0336-7 CrossRefPubMedGoogle Scholar
  15. 15.
    Sho M, Akahori T, Tanaka T, Kinoshita S, Tamamoto T, Nomi T, Yamato I, Hokuto D, Yasuda S, Kawaguchi C, Nishiofuku H, Marugami N, Enomonoto Y, Kasai T, Hasegawa M, Kichikawa K, Nakajima Y (2013) Pathological and clinical impact of neoadjuvant chemoradiotherapy using full-dose gemcitabine and concurrent radiation for resectable pancreatic cancer. J Hepatobiliary Pancreat Sci 20(2):197–205.  https://doi.org/10.1007/s00534-012-0532-8 CrossRefGoogle Scholar
  16. 16.
    Hashimoto A, Tanaka T, Sho M, Nishiofuku H, Masada T, Sato T, Marugami N, Anai H, Sakaguchi H, Kanno M, Tamamoto T, Hasegawa M, Nakajima Y, Kichikawa K (2016) Adjuvant hepatic arterial infusion chemotherapy after resection for pancreatic cancer using coaxial catheter-port system compared with conventional system. Cardiovasc Intervent Radiol 39(6):831–839.  https://doi.org/10.1007/s00270-016-1292-7 CrossRefPubMedGoogle Scholar
  17. 17.
    Kuhlmann KF, de Castro SM, Wesseling JG, ten Kate FJ, Offerhaus GJ, Busch OR, van Gulik TM, Obertop H, Gouma DJ (2004) Surgical treatment of pancreatic adenocarcinoma; actual survival and prognostic factors in 343 patients. Eur J Cancer 40(4):549–558. doi: https://doi.org/10.1016/j.ejca.2003.10.026 CrossRefGoogle Scholar
  18. 18.
    Han SS, Jang JY, Kim SW, Kim WH, Lee KU, Park YH (2006) Analysis of long-term survivors after surgical resection for pancreatic cancer. Pancreas 32(3):271–275.  https://doi.org/10.1097/01.mpa.0000202953.87740.93 CrossRefPubMedGoogle Scholar
  19. 19.
    Winter JM, Cameron JL, Campbell KA, Arnold MA, Chang DC, Coleman J, Hodgin MB, Sauter PK, Hruban RH, Riall TS, Schulick RD, Choti MA, Lillemoe KD, Yeo CJ (2006) 1423 pancreaticoduodenectomies for pancreatic cancer: a single-institution experience. J Gastrointest Surg 10(9):1199–1210; discussion 1210-1.  https://doi.org/10.1016/j.gassur.2006.08.018 CrossRefGoogle Scholar
  20. 20.
    Ferrone CR, Pieretti-Vanmarcke R, Bloom JP, Zheng H, Szymonifka J, Wargo JA, Thayer SP, Lauwers GY, Deshpande V, Mino-Kenudson M, Fernandez-del Castillo C, Lillemoe KD, Warshaw AL (2012) Pancreatic ductal adenocarcinoma: long-term survival does not equal cure. Surgery 152(3 Suppl 1):S43–S49.  https://doi.org/10.1016/j.surg.2012.05.020 CrossRefPubMedPubMedCentralGoogle Scholar
  21. 21.
    Oettle H, Post S, Neuhaus P, Gellert K, Langrehr J, Ridwelski K, Schramm H, Fahlke J, Zuelke C, Burkart C, Gutberlet K, Kettner E, Schmalenberg H, Weigang-Koehler K, Bechstein WO, Niedergethmann M, Schmidt-Wolf I, Roll L, Doerken B, Riess H (2007) Adjuvant chemotherapy with gemcitabine vs observation in patients undergoing curative-intent resection of pancreatic cancer: a randomized controlled trial. JAMA 297(3):267–277.  https://doi.org/10.1001/jama.297.3.267 CrossRefPubMedGoogle Scholar
  22. 22.
    Ueno H, Kosuge T, Matsuyama Y, Yamamoto J, Nakao A, Egawa S, Doi R, Monden M, Hatori T, Tanaka M, Shimada M, Kanemitsu K (2009) A randomised phase III trial comparing gemcitabine with surgery-only in patients with resected pancreatic cancer: Japanese study group of adjuvant therapy for pancreatic cancer. Br J Cancer 101(6):908–915.  https://doi.org/10.1038/sj.bjc.6605256 CrossRefPubMedPubMedCentralGoogle Scholar
  23. 23.
    Neoptolemos JP, Stocken DD, Bassi C, Ghaneh P, Cunningham D, Goldstein D, Padbury R, Moore MJ, Gallinger S, Mariette C, Wente MN, Izbicki JR, Friess H, Lerch MM, Dervenis C, Olah A, Butturini G, Doi R, Lind PA, Smith D, Valle JW, Palmer DH, Buckels JA, Thompson J, McKay CJ, Rawcliffe CL, Buchler MW (2010) Adjuvant chemotherapy with fluorouracil plus folinic acid vs gemcitabine following pancreatic cancer resection: a randomized controlled trial. JAMA 304(10):1073–1081.  https://doi.org/10.1001/jama.2010.1275 CrossRefPubMedGoogle Scholar
  24. 24.
    Uesaka K, Boku N, Fukutomi A, Okamura Y, Konishi M, Matsumoto I, Kaneoka Y, Shimizu Y, Nakamori S, Sakamoto H, Morinaga S, Kainuma O, Imai K, Sata N, Hishinuma S, Ojima H, Yamaguchi R, Hirano S, Sudo T, Ohashi Y (2016) Adjuvant chemotherapy of S-1 versus gemcitabine for resected pancreatic cancer: a phase 3, open-label, randomised, non-inferiority trial (JASPAC 01). Lancet 388(10041):248–257.  https://doi.org/10.1016/s0140-6736(16)30583-9 CrossRefPubMedGoogle Scholar
  25. 25.
    Conroy T, Desseigne F, Ychou M, Bouche O, Guimbaud R, Becouarn Y, Adenis A, Raoul JL, Gourgou-Bourgade S, de la Fouchardiere C, Bennouna J, Bachet JB, Khemissa-Akouz F, Pere-Verge D, Delbaldo C, Assenat E, Chauffert B, Michel P, Montoto-Grillot C, Ducreux M (2011) FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med 364(19):1817–1825.  https://doi.org/10.1056/NEJMoa1011923 CrossRefGoogle Scholar
  26. 26.
    Von Hoff DD, Ervin T, Arena FP, Chiorean EG, Infante J, Moore M, Seay T, Tjulandin SA, Ma WW, Saleh MN, Harris M, Reni M, Dowden S, Laheru D, Bahary N, Ramanathan RK, Tabernero J, Hidalgo M, Goldstein D, Van Cutsem E, Wei X, Iglesias J, Renschler MF (2013) Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. N Engl J Med 369(18):1691–1703.  https://doi.org/10.1056/NEJMoa1304369 CrossRefGoogle Scholar
  27. 27.
    Wang-Gillam A, Li CP, Bodoky G, Dean A, Shan YS, Jameson G, Macarulla T, Lee KH, Cunningham D, Blanc JF, Hubner RA, Chiu CF, Schwartsmann G, Siveke JT, Braiteh F, Moyo V, Belanger B, Dhindsa N, Bayever E, Von Hoff DD, Chen LT (2016) Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial. Lancet 387(10018):545–557.  https://doi.org/10.1016/s0140-6736(15)00986-1 CrossRefPubMedGoogle Scholar
  28. 28.
    Kim SS, Nakakura EK, Wang ZJ, Kim GE, Corvera CU, Harris HW, Kirkwood KS, Hirose R, Tempero MA, Ko AH (2016) Preoperative FOLFIRINOX for borderline resectable pancreatic cancer: is radiation necessary in the modern era of chemotherapy? J Surg Oncol 114(5):587–596.  https://doi.org/10.1002/jso.24375 CrossRefPubMedGoogle Scholar
  29. 29.
    Rashid OM, Pimiento JM, Gamenthaler AW, Nguyen P, Ha TT, Hutchinson T, Springett G, Hoffe S, Shridhar R, Hodul PJ, Johnson BL, Illig K, Armstrong PA, Centeno BA, Fulp WJ, Chen DT, Malafa MP (2016) Outcomes of a clinical pathway for borderline resectable pancreatic cancer. Ann Surg Oncol 23(4):1371–1379.  https://doi.org/10.1245/s10434-015-5006-1 CrossRefPubMedGoogle Scholar
  30. 30.
    Sho M, Akahori T, Tanaka T, Kinoshita S, Nagai M, Nishiwada S, Tamamoto T, Nishiofuku H, Ohbayashi C, Hasegawa M, Kichikawa K, Nakajima Y (2015a) Optimal indication of neoadjuvant chemoradiotherapy for pancreatic cancer. Langenbeck's Arch Surg 400(4):477–485.  https://doi.org/10.1007/s00423-015-1304-0 CrossRefGoogle Scholar
  31. 31.
    Sho M, Akahori T, Tanaka T, Kinoshita S, Nagai M, Tamamoto T, Ohbayashi C, Hasegawa M, Kichikawa K, Nakajima Y (2015b) Importance of resectability status in neoadjuvant treatment for pancreatic cancer. J Hepatobiliary Pancreat Sci 22(7):563–570.  https://doi.org/10.1002/jhbp.258 CrossRefPubMedGoogle Scholar
  32. 32.
    Takahashi H, Akita H, Tomokuni A, Kobayashi S, Ohigashi H, Fijiwara Y, Yano M, Sakon M, Ishikawa O (2016) Preoperative gemcitabine-based chemoradiation therapy for borderline resectable pancreatic cancer: impact of venous and arterial involvement status on surgical outcome and pattern of recurrence. Ann Surg 264(6):1091–1097.  https://doi.org/10.1097/sla.0000000000001547 CrossRefPubMedGoogle Scholar
  33. 33.
    Katz MH, Fleming JB, Bhosale P, Varadhachary G, Lee JE, Wolff R, Wang H, Abbruzzese J, Pisters PW, Vauthey JN, Charnsangavej C, Tamm E, Crane CH, Balachandran A (2012) Response of borderline resectable pancreatic cancer to neoadjuvant therapy is not reflected by radiographic indicators. Cancer 118(23):5749–5756.  https://doi.org/10.1002/cncr.27636 CrossRefPubMedGoogle Scholar
  34. 34.
    Kruger S, Haas M, Burger PJ, Ormanns S, Modest DP, Westphalen CB, Michl M, Kleespies A, Angele MK, Hartwig W, Bruns CJ, Niyazi M, Roeder F, Kirchner T, Werner J, Heinemann V, Boeck S (2016) Isolated pulmonary metastases define a favorable subgroup in metastatic pancreatic cancer. Pancreatology 16(4):593–598.  https://doi.org/10.1016/j.pan.2016.03.016 CrossRefPubMedGoogle Scholar
  35. 35.
    Yamashita K, Miyamoto A, Hama N, Asaoka T, Maeda S, Omiya H, Takami K, Doki Y, Mori M, Nakamori S (2015) Survival impact of pulmonary metastasis as recurrence of pancreatic ductal adenocarcinoma. Dig Surg 32(6):464–471.  https://doi.org/10.1159/000439545 CrossRefPubMedGoogle Scholar
  36. 36.
    Papavasiliou P, Hoffman JP, Cohen SJ, Meyer JE, Watson JC, Chun YS (2014) Impact of preoperative therapy on patterns of recurrence in pancreatic cancer. HPB (Oxford) 16(1):34–39.  https://doi.org/10.1111/hpb.12058 CrossRefGoogle Scholar
  37. 37.
    Thomas RM, Truty MJ, Nogueras-Gonzalez GM, Fleming JB, Vauthey JN, Pisters PW, Lee JE, Rice DC, Hofstetter WL, Wolff RA, Varadhachary GR, Wang H, Katz MH (2012) Selective reoperation for locally recurrent or metastatic pancreatic ductal adenocarcinoma following primary pancreatic resection. J Gastrointest Surg 16(9):1696–1704.  https://doi.org/10.1007/s11605-012-1912-8 CrossRefPubMedGoogle Scholar
  38. 38.
    Wangjam T, Zhang Z, Zhou XC, Lyer L, Faisal F, Soares KC, Fishman E, Hruban RH, Herman JM, Laheru D, Weiss M, Li M, De Jesus-Acosta A, Wolfgang CL, Zheng L (2015) Resected pancreatic ductal adenocarcinomas with recurrence limited in lung have a significantly better prognosis than those with other recurrence patterns. Oncotarget 6(34):36903–36910.  https://doi.org/10.18632/oncotarget.5054 CrossRefPubMedPubMedCentralGoogle Scholar
  39. 39.
    Groot VP, Rezaee N, Wu W, Cameron JL, Fishman EK, Hruban RH, Weiss MJ, Zheng L, Wolfgang CL, He J (2018) Patterns, timing, and predictors of recurrence following pancreatectomy for pancreatic ductal adenocarcinoma. Ann Surg 267(5):936–945.  https://doi.org/10.1097/sla.0000000000002234 CrossRefPubMedGoogle Scholar

Copyright information

© Springer-Verlag GmbH Germany, part of Springer Nature 2018

Authors and Affiliations

  • Kenji Nakagawa
    • 1
  • Takahiro Akahori
    • 1
  • Satoshi Nishiwada
    • 1
  • Minako Nagai
    • 1
  • Kota Nakamura
    • 1
  • Toshihiro Tanaka
    • 2
  • Tetsuro Tamamoto
    • 3
  • Chiho Ohbayashi
    • 4
  • Masatoshi Hasegawa
    • 3
  • Kimihiko Kichikawa
    • 2
  • Naoya Ikeda
    • 1
  • Masayuki Sho
    • 1
  1. 1.Department of SurgeryNara Medical UniversityNaraJapan
  2. 2.Department of RadiologyNara Medical UniversityNaraJapan
  3. 3.Department of Radiation OncologyNara Medical UniversityNaraJapan
  4. 4.Department of Diagnostic PathologyNara Medical UniversityNaraJapan

Personalised recommendations